69results about How to "Reduce proteinuria" patented technology

The invention relates to a Chinese medicinal formula for treating chronic renal failure. The formula consists of the following raw materials by weight (counted by gram): 12-16g of roasted aconite (decocted firstly), 12-16g of south dodder seed, 15-22g of cortex eucommiae, 15-22g of astragalus, 15-22g of dangshen, 15-22g of indian buead, 12-18g of large-head atractylodes rhizome, 15-22g of Chinese yam, 12-18g of pokeberry root, 12-16g of areca peel, 15-22g of umbellate pore fungus, 20-30g of rhubarb, 25-32g of red-rooted salvia root, 25-32g of honeysuckle flower, 25-32g of dandelion and 15-22g of sweet basil. After being taken by a patient suffering from chronic renal failure, a medicament prepared in the weight ratio has the effects of exciting potential, improving physique, improving symptoms, promoting the excretion of metabolic waste, relieving the state of an illness and prolonging life.

The invention discloses a traditional Chinese medicine composition for treating a chronic renal failure and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following components in percentage by weight: 5%-20% of processed radix aconiti carmichaeli, 5%-20% of poria cocos, 2%-17% of rhizoma atractylodis macrocephalae, 5%-20% of Chinese herbaceous peony, 5%-20% of ginger, 6%-21% of rheum officinale, 18%-33% of scutellaria baicalensis and 12%-27% of salviae miltiorrhizae. The traditional Chinese medicine composition for treating the chronic renal failure disclosed by the invention has a significant effect on treatment of the chronic renal failure caused by the syndrome of qi deficiency (yang) of the spleen and kidneys and exuberance of internal damp turbidity.

The present invention relates to recombinant protein of hypoglycemic peptide and human lysozyme and its use. The hypoglycemic peptide in the fusion protein is GLP-1 or its analog and has amino acid sequence of one of those shown in SEQ ID Nos. 1-5; and the human lysozyme has amino acid sequence as shown in SEQ ID No. 6. The hypoglycemic peptide and the human lysozyme are connected in one of the following four connection modes: hypoglycemic peptide-connecting peptide-human lysozyme, hypoglycemic peptide-human lysozyme, human lysozyme-connecting peptide-hypoglycemic peptide and human lysozyme-hypoglycemic peptide. The fusion protein has the hypoglycemic activity of GLP-1 maintained, prolonged half life, as well as anti-infective activity and AGE level-lowering function of human lysozyme, and may be used in preparing medicine for treating diabetes and diabetes complication.

The invention discloses a sharpleaf galangal fruit extract capable of treating chronic kidney diseases. The extract is prepared by the following steps: grinding sharpleaf galangal fruits to remove the shells, adding a certain amount of ethanol, carrying out reflux extraction, collecting the extract, making the extract go through macroporous resin, eluting the macroporous resin by low-concentration ethanol to remove the impurities, then eluting the macroporous resin by high-concentration ethanol, condensing to obtain extract, separating the extract in a silica gel column, and carrying out crystallization so as to obtain the sharpleaf galangal fruit extract. According to the pathogenesis of chronic kidney diseases and on the basis of traditional Chinese medicine theory, the inventor researches the chemical components and the clinical curative effect of sharpleaf galangal fruit. The results of a great number of experiments show that the prepared sharpleaf galangal fruit extract (nootkatone) can prominently reduce proteinuria, can also obviously reduce the levels of serum creatinine and urea nitrogen, has a good kidney protective effect, and can be used to prevent and treat chronic kidney diseases.

The invention relates to a traditional Chinese medicine composition for treating diabetic nephropathy. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 25-35 parts of astragalus membranaceus, 15-25 parts of cordyceps cicadae, 8-12 parts of taxus chinensis, 1-5 parts of saffron, 10-15 parts of Chinese wolfberry, 10-20 parts of lucid ganoderma, 15-25 parts of radix puerariae, 15-25 parts of gynostemma pentaphylla, 10-20 parts of wine-treated rhubarb and 3-9 parts of liquorice. The invention further provides an application of the traditional Chinese medicine composition. The traditional Chinese medicine composition disclosed by the invention has a very good protection effect on the kidney of a rat with diabetic nephropathy,and can effectively reduce kidney weight index, blood sugar, serum creatinine and urea nitrogen, reduce proteinuria and improve pathological injury of kidney tissues of the rat with diabetic nephropathy. According to the application disclosed by the invention, the effects of reducing proteinuria and protecting kidneys are achieved by down-regulating the expression of TGF-beta1, p-Smad2, p-Smad3 and alpha-SMA proteins in kidney tissues of DN rats.

The invention relates to the technical field of medicine, in particular to the application of astragalus extract to preparation of NF-kappa B inhibitor. Experiments prove that the astragalus extract can inhibit chronic nephritis NF-kappa B expression and further affect the level of IL-6, TNF-alpha, TGF-beta 1 and MCP-1 and reduce proteinuria. Therefore, the astragalus extract can serve as an active component for inhibiting chronic kidney disease NF-kappa B and be used for preparing drugs for treating chronic kidney disease.

The invention discloses a traditional Chinese medicine compound composition for delaying progress of chronic kidney diseases and clinical application of the traditional Chinese medicine compound composition. The traditional Chinese medicine compound composition which is a pure traditional Chinese medicine preparation comprises a plurality of traditional Chinese medicines including radix astragali, radix angelicae sinensis, rhizoma chuanxiong, radix achyranthis bidentatae, radix et rhizoma rhei preparata, serissa japonica, radix glycyrrhizae, hedyotis diffusa, herba centellae and caulis bambusae in taenia. The traditional Chinese medicine compound composition and the clinical application have the advantages that as shown by completed pharmacodynamical research and clinical research, the kidney fibrotic lesion degrees of experimental animals can be obviously improved by the preparation, the creatinine levels can be lowered, and kidney functions can be protected; the kidney pathological lesion degrees related to the chronic kidney diseases can be improved, and mechanisms related to curative effects are verified from the angle of molecular biology; as shown by clinical research, proteinuria and hematuria conditions related to the chronic kidney diseases can be reduced by the traditional Chinese medicine preparation, and deterioration of creatinine clearance rates (computed by the aid of Cockcraft-Gault formulas) of patients suffering from the chronic kidney diseases can be obviously controlled; the total treatment effective rate can reach 98% at least, expenditure required for treating the diseases can be reduced for the patients, the stable curative effects can be realized, and the traditional Chinese medicine compound composition is free of obvious toxic and side effects.

The invention relates to a drug for treating chronic kidney disease proteinuria, which is a capsules prepared as follows: the materials are astragalus, Oriental Waterplantain Rhizome, Chinese Magnolivine Fruit, fried foxnut and node of lotus rhizome, which are added to water to be decocted, and the decoction solution is concentrated and dried. The drug has the advantages of kidney invigorating, diuresis inducing and stranguria treating, blood activating and stasis removing, swelling reducing and pain alleviating, heat-clearing and detoxifying, body fluid regenerating and thirst quenching, darrhea relieving, cough relieving and bleeding stopping, which has the function of body immunity regulation and reinforcing, and is suitable for the patient with chronic kidney disease and chronic renal failure proteinuria; the drug can effectively reduce proteinuria, increase plasma albumin, reduce the pathological changes of kidney and improve hemorheology indexes, which has a certain controlling effect on hematuria and proteinuria. In clinical verification, the drug has the advantages of fast therapeutic effect, good efficacy and small side effect.

The invention provides methods of treating proteinuria in an individual such as human by administering an effective amount of an agent that reduces the level of anti-dsDNA antibodies (such as a dsDNA epitope as in the form of an epitope-presenting carrier or an epitope-presenting valency platform molecule like LJP 394) to the individual. The invention also provides methods of determining responsiveness of the individual to (or selecting an individual for continuing) treatment of an agent that reduces anti-dsDNA antibodies by determining reduction of proteinuria after a certain period of time upon initiation of the treatment.

Compositions are directed to the treatment of kidney diseases in a cell-specific manner. Methods of treating kidney diseases comprise the use of the compositions. Assays for identification of further compounds are provided. Biomarkers for predisposition to kidney diseases and diagnosis are identified.

The invention discloses a process for preparing low-molecular-weight fucoidan, wherein the low-molecular-weight fucoidan is prepared through the process steps of hydrochloric acid degradation, desalination, ion exchange column elution and the like. Proved by pharmacological activity experiments, the low-molecular-weight fucoidan prepared by adopting the method disclosed by the invention is capable of obviously improving renal function, reducing proteinuria, slowing glomerular sclerosis and playing a role of protecting kidney. Proved by animal experiments, the effect of the low-molecular-weight fucoidan is obviously better than that of fucoidan with the same dose, so that the low-molecular-weight fucoidan disclosed by the invention can be used for preparing drugs for treating diabetic nephropathy or can be directly used as a drug for treating the diabetic nephropathy.

The invention discloses a new dosage form of Huangqi decoction free decoction granules for treating diabetic nephropathy and its application. 10‑30 parts of Ophiopogon japonicus, 5‑15 parts of Schisandra chinensis, 5‑15 parts of Zhi Licorice and 25‑35 parts of Rehmannia glutinosa; made according to the following method: Step 1: Take medicinal materials, chop them, add water to soak, and decoct Multiple times, collect each decoction and combine; Step 2: After decoction is centrifuged or sedimentation filtered, concentrate, place in refrigeration, add ethanol, mix well, and place overnight; Step 3: Take out the next day and filter, precipitate The substance is washed with ethanol, the washing liquid is combined with the filtrate, and after the ethanol is recovered under reduced pressure, it is concentrated and then placed in a cold place to stand still, filtered, and the filtrate is evaporated at low temperature to a thick paste to obtain an extract; step 4: finally combine the extract with The auxiliary materials are kneaded, granulated, and dried to obtain Huangqi Decoction Free Fried Granules. The invention overcomes the disadvantages of Huang's decoction preparation, decoction, inconvenient carrying, easy deterioration, bitter soup and the like.

The invention relates to a traditional Chinese medicine preparation for treating diabetic nephropathy and preparation and administration methods thereof. The traditional Chinese medicine preparation is prepared from the following raw materials: astragalus membranaceus, radix pseudostellariae, semen cuscutae, cornus officinalis sieb et zucc, bighead atractylodes rhizome, the root of kudzu vine, gorgon fruit powder, fructus rosae laevigatae powder, periostracum cicada powder, eupatorium powder, agastache rugosus powder, rheum officinale powder, scutellaria baicalensis powder, radix rehmanniae recen, pseudo-ginseng powder and salviae miltiorrhizae. According to the theory of traditional Chinese medicine, treatment determination based on syndrome differentiation is performed by combining features of incidence of diabetic nephropathy and the condition of kidney injury, so that a traditional Chinese medicine compound preparation is formulated; through long-term clinical observation, the clinical symptoms of a patient are improved, proteinuria, urea nitrogen and serum creatinine are decreased to different extents, development of nephropathy is delayed, the renal function is improved, and the preparation plays a role of treating both symptoms and root causes.

The invention relates to Chinese medicine used for treating chronic kidney disease, especially for treating kidney inflammation, invisible kidney inflammation and nephritic syndrome, and a preparation method of the Chinese medicine. The medicine is made of yerbadetajo, Ligustrum lucidum, Leonurus japonicus, Salvia, Rehmanniae, Lonicera confuse, Madder, Lycium Chinese Mill and Scorpion. The medicine has the efficacy of replenishing vital essence, tonifying kidney-yin, activating blood and dissolving stasis. The medicine is mainly applicable to treating kidney deficiency as well as the chronic kidney disease, the invisible kidney inflammation and the nephritic syndrome and also can be used for treating the nephritic syndrome in conjunction with western medicine such as Glucocorticoid. The medicine can improve curative effect, put off recurrence and reduce the times of recurrence. The medicine of the invention can be made into any formulation which is suitable for clinical treatment, including powders, decoction, mixture, oral liquor, capsule, granular formulation and a condensed pill and so on.

The present invention discloses 5-methyl-1-(substituted phenyl)-2(1H)-pyridones having the ability to reduce proteinuria and for treating kidney diseases. The ability to reduce proteinuria has a renoprotective effect for slowing the progression of kidney diseases. A representative example of 5-methyl-(1-substituted phenyl)-2(1H)-pyridones is 1-(3′-fluorophenyl)-5-methyl-2(1H)-pyridone, AKF-PD. Accordingly, the present invention provides compositions comprising one or more compounds selected from the group consisting of 5-methyl-1-(substituted phenyl)-2(1H)-pyridones and methods of using the same to treat proteinuria and kidney diseases.

The invention discloses a medicine for treating kidney-deficiency and collateral stasis-type diabetic nephropathy in IV stage. The medicine is prepared from 25 to 35g of radix astragali seu hedysari,25 to 35g of raw oysters, 25 to 35g of rhizoma smilacis glabrae, 25 to 35g of semen euryales, 13 to 18g of hedyotis diffusa, 8 to 15g of winged euonymus twigs, 8 to 13g of radix salviae miltiorrhizae,8 to 12g of radix rehmanniae, 7 to 12g of Chinese yams, 8 to 12g of cornus officinalis and 5 to 12g of mantis egg-case. The medicine is prepared by removing radix scrophulariae, rhizoma atractylodis,radix puerariae, flos carthami, rhizoma alismatis and fructus rosae laevigatae and adding the raw oysters, the hedyotis diffusa, the winged euonymus twigs, the salviae miltiorrhizae and the mantis egg-case on the basis of a pancreas-nourishing and kidney tonifying formula, so that the effects of promoting blood circulation to remove stasis, removing blood stasis, dredging collaterals and clearingaway heat and toxic materials are enhanced, and the effects of improving kidney function and reducing urine protein are achieved.

The invention discloses a drug for treating renal-deficiency humid-heat type chronic nephritis. The drug is prepared from the following material medicines in parts by weight: 20-40 parts of astragalus membranaceus, 8-12 parts of white atractylodes rhizome, 8-12 parts of pulp of dogwood fruit, 10-30 parts of eucommia ulmoides, 10-20 parts of rhizoma alismatis, 10-30 parts of herba pyrrosiae, 10-30 parts of oldenlandia diffusa and 3-7 parts of pseudo-ginseng. After being proved by a pharmacological experiment, the drug disclosed by the invention has a better function in treating chronic nephritis, is safe to take, suitable for preventing and treating chronic nephritis. The invention further discloses a preparation method and an application of the drug.

The invention discloses a traditional Chinese medicinal compound preparation for treating IgA nephrosis with hyperuricemia, and a preparation method and a use thereof. The traditional Chinese medicinal compound preparation comprises 25-35 parts of buffalo horns, 10-20 parts of dry rehmannia root, 8-16 parts of radix paeoniae rubra, 6-14 parts of Cortex Moutan, 25-35 parts of Lithospermum erythrorhizon, 8-16 parts of Atractylodes lancea, 8-16 parts of Amur Corktree Bark, 8-16 parts of Medicinal Cyathula Root, 25-35 parts of coix seeds, 25-35 parts of Glabrous Greenbrier Rhizome, 8-16 parts of rhizome of Dioscorea septemloba Thunb, 8-16 parts of Semen plantaginis, 8-16 parts of Semen Sinapis albae, 3-9 parts of rheum officinale, 10-20 parts of Rhizoma Atractylodis Macrocephalae and 8-16 parts of hawthorn fruits. The preparation adopting traditional Chinese medicinal components has mild and non-irritating medicinal effects, has the efficacy of clearing heat and cooling blood, and removing dampness and purging turbidity, can reinforce treatment of IgA nephrosis, effectively reduce proteinuria, uric acid and blood fat in order to restore the kidney functions, can treat the IgA nephrosis with hyperuricemia, is safe to take, and also has the advantages of reliable curative effect, and difficult recurrence of hyperuricemia.

Provided herein are nutritional, or therapeutic, compositions and methods of use in primarily treating kidney patients suffering from low serum albumin. The compositions are divided into four formulations, comprising: 1) the magnesium salt and/or the calcium salt of the alpha keto acids of: α-leucine, α-valine, α-isoleucine, α-phenylalanine, α-hydroxy methionine; and/or α-tryptophan, and/or α-tyrosine; 2) L-lysine monoacetate, L-threonine; and/or 3) histidine, tryptophan, and tyrosine, as amino acids or base acids. The specific formulation administered depends in part upon which stage 2-5 of renal disease the patient has. The invention further comprises methods of treatment of disorders associated with low serum albumin using the composition as an over-the-counter pill. The patient's serum albumin is tested on a periodic basis and the selected composition and dose are adjusted accordingly. And the invention comprises method of making α-leucine, α-valine, α-isoleucine, a-tyrosine and α-tryptophan in a multi-step process.

The invention discloses Shenkangding Jiaonang for treating chronic nephrosis. The Shenkangding Jiaonang is prepared from the following raw materials in part by weight: 27 to 33 parts of sculellaria barbata, 27 to 33 parts of winged euonymus twig, 27 to 33 parts of oldenlandia diffusa, 8 to 12 parts of paniculate swallowwort root, 13 to 17 parts of alisma plantagoaquatica, 13 to 17 parts of fried atractylodes lancea, 27 to 33 parts of lightyellow sophora root, 8 to 12 parts of honeysuckle, 8 to 12 parts of hiraute shiny bugleweed herb, 17 to 23 parts of root of red-rooted salvia, 13 to 17 parts of Chinese pyrola herb, 22 to 28 parts of hairyvein agrimonia herb and bud, 11 to 14 parts of root of rehmannia, 13 to 17 parts of fried bighead atractylodes rhizome, 8 to 12 parts of eucommia bark, and 8 to 12 parts of safflower. The invention has the advantages of eliminating the pathogenic factor and eliminating body resistance by strengthening the spleen, tonifying kidney and qi, nourishing yin, activating blood circulation, promoting dieresis, detoxifying and removing stasis. Meanwhile, Shenkangding Jiaonang can reduce proteinuria and hematuresis and can improve kidney functions. The Shenkangding Jiaonang also has the characteristics of good treatment effect, readily available material, simple preparation process, low preparation cost, low price that can be afforded by ordinary people, safety, no toxic or side effects, and convenient administration.

A Chinese medicine for preventing and treating nephrosis is prepared from 4 Chinese-medicinal materials including radical lobelia, cordyceps, astragalus root, etc through extracting, proportional mixing, pulverizing and granulating. Its advantage is high curative effect.

The invention discloses a traditional Chinese medicine preparation capable of reducing hematuria and proteinuria of a patient with lupus nephritis. The traditional Chinese medicine preparation is made by the following raw materials, in parts by weight: bupleurum 120, prepared pinellia 90, pilose asiabell root 120, skullcap 90, prepared rehmannia root 120, red salvia root 90, notoginseng 90, motherwort 150, cordate houttuynia 150, Cherokee rose 120, Job's tears root 120, Chinese yam 90, and prepared licorice 60. The traditional Chinese medicine preparation is made according to a certain weight part, and is capable of reinforcing the spleen to replenish qi, tonifying the kidney to control the nocturnal, removing pathogenic heat from blood, dissolving the stagnant and stopping bleeding, detoxicating and resolving the mass after being taken orally. The traditional Chinese medicine preparation can effectively reduce hematuria and proteinuria of the patient and delay or reduce complications.

The invention discloses a Chinese medicinal composition for preventing and treating proteinuria. The composition comprises the following raw materials in parts by weight: 1-20 parts of silkworm cocoonshell, 1-20 parts of corn stigma, 0-20 parts of astragalus root, 0-20 parts of salvia miltiorrhiza and 0-20 parts of ligusticum chuanxiong. In addition, the invention also discloses the application of the traditional Chinese medicine composition in preparing medicines and health products for preventing and treating proteinuria. The composition has been proved by animal experiments and clinical trials that the safety is good and the curative effect is good, and the diabetic nephropathy, membranous nephropathy, primary nephritis, IgA nephropathy, purpuric nephritis, lupus nephritis, hypertensive nephropathy and gout can be reduced. Proteinuria caused by different causes such as kidney disease, chronic renal failure, chronic nephritis, nephrotic syndrome, lupus nephritis, urinary tract infection. The traditional Chinese medicine composition is capable of improving clinical symptoms, has small toxic and side effects, has good clinical application prospect, and has simple extraction process, is easy to prepare, and reduces preparation cost.